selected scholarly activity
-
chapters
- A Discussion of the Use of Virtual Reality in Dementia. 123-136. 2012
-
conferences
- Risk factors for intracranial metastasis in stage III NSCLC after chemoradiation. Radiotherapy and Oncology. S1066-S1066. 2023
- Tumour Associated Neutrophils (TAN): An H&E-based Biomarker Predicting Poor Response to Anti-PD-1 Monotherapy in Lung Adenocarcinomas with High PD-L1 Expression. Laboratory Investigation. S1610-S1610. 2023
-
journal articles
- Association of Circadian Timing of Initial Infusions of Immune Checkpoint Inhibitors with Survival in Advanced Melanoma. Immunotherapy. 15:819-826. 2023
- Management of metastatic head and neck Cancer: An all-in, kitchen-sink Approach?. Oral Oncology. 143:106444-106444. 2023
- PO-1332 Risk factors for intracranial metastasis in stage III NSCLC after chemoradiation. Radiotherapy and Oncology. 182:S1066-S1066. 2023
- Survivals following discontinuation of PD-1 inhibitor treatment in advanced melanoma patients. Melanoma Research. 33:50-57. 2023
- Can Oncogenic Driver Alterations be Responsible for the Lack of Immunotherapy Efficacy in First-line Advanced Urothelial Carcinoma?. European Urology. 83:1-2. 2023
- Survival outcomes and predicting intracranial metastasis in stage III non-small cell lung cancer treated with definitive chemoradiation: Real-world data from a tertiary cancer center. Cancer Treatment and Research Communications. 36:100747-100747. 2023
- Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed?. Journal of Clinical Oncology. 40:3573-3575. 2022
- Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients. Current Oncology. 29:7953-7963. 2022
- Complete Response and Survival Outcomes in Patients with Advanced Cancer on Immune Checkpoint Inhibitors. Immunotherapy. 14:777-787. 2022
- No Association Between BMI and Immunotoxicity or Clinical Outcomes for Immune Checkpoint Inhibitors. Immunotherapy. 14:765-776. 2022
- Should the control arms of randomized trials have an expiry date?. Nature Reviews Clinical Oncology. 19:425-426. 2022
- Improved Overall Survival in Dual Compared to Single Immune Checkpoint Inhibitors in BRAF V600-Negative Advanced Melanoma. Melanoma Management. 9:MMT60. 2022
- Real-World Evidence of Systemic Therapy Sequencing on Overall Survival for Patients with Metastatic BRAF-Mutated Cutaneous Melanoma. Current Oncology. 29:1501-1513. 2022
- Optimal first-line immune checkpoint inhibitor treatment in lung cancer: how to choose?. Future Oncology. 18:635-638. 2022
- Safety and efficacy analysis of pembrolizumab dosing patterns in patients with advanced melanoma and non-small cell lung cancer. Journal of Oncology Pharmacy Practice. 28:87-95. 2022
- Venous Thromboembolism Events in Patients with Advanced Cancer on Immune Checkpoint Inhibitors. Immunotherapy. 14:23-30. 2022
- Adjuvant Immune Checkpoint Inhibition in Muscle-invasive Bladder Cancer: Is It Ready for Prime Time?. European Urology. 80:679-681. 2021
- A Systematic Review and Meta-analysis of Dual Therapy in Patients With Advanced Renal Cell Carcinoma of Favourable Risk. Urology. 157:8-14. 2021
- Safety and Clinical Outcomes of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Diseases. Journal of immunotherapy (Hagerstown, Md. : 1997). 44:362-370. 2021
- Management of Favorable-risk Advanced Renal Cell Carcinoma: Is Dual Therapy the Answer?. European Urology Open Science. 30:44-46. 2021
- Impact of Baseline Corticosteroids on Immunotherapy Efficacy in Patients With Advanced Melanoma. Journal of immunotherapy (Hagerstown, Md. : 1997). 44:167-174. 2021
- A Case of Successful Pembrolizumab Rechallenge in a Patient with Non-Small-Cell Lung Cancer and Grade 3 Dermatomyositis. Immunotherapy. 13:477-481. 2021
- Prognosticating Role of Serum Eosinophils on Immunotherapy Efficacy in Patients with Advanced Melanoma. Immunotherapy. 13:217-225. 2021
- A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors. Cancer Treatment and Research Communications. 27:100330-100330. 2021
- Consolidative durvalumab outcomes in stage III non-small cell lung cancer in a multi-centre study. Cancer Treatment and Research Communications. 29:100496-100496. 2021
- Safety of Immunotherapy Rechallenge After Immune-related Adverse Events in Patients With Advanced Cancer. Journal of immunotherapy (Hagerstown, Md. : 1997). 44:41-48. 2021
- Emergency Department Utilization for Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis of Identification and Outcomes for Those Presenting for Immune-Related Adverse Events. Current Oncology. 28:52-59. 2020
- Serum Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Prognosticating Immunotherapy Efficacy. Immunotherapy. 12:785-798. 2020
- Correlation between different carboplatin dosing patterns and its toxicity analysis in patients with advanced lung cancers: A retrospective study. Journal of Oncology Pharmacy Practice. 25:1082-1088. 2019
- The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population. Journal of Geriatric Oncology. 10:411-414. 2019
- Predictors of Immunotherapy-Induced Immune-Related Adverse Events. Current Oncology. 25:403-410. 2018
- Motivation and preferences of exercise programmes in patients with inoperable metastatic lung cancer: a need assessment. Supportive Care in Cancer. 24:129-137. 2016
- Case Based Learning Teaching Methodology in Undergraduate Health Sciences. Revue interdisciplinaire des sciences de la santé - Interdisciplinary Journal of Health Sciences. 2:48-48.